LONDON – Belluscura PLC, a medical device company specializing in oxygen enrichment technology, has announced a new joint venture with Separation Design Group and an undisclosed major medical device company to develop oxygen-based wound care solutions. The collaboration aims to address the growing wound care market through innovative treatments, including continuously diffused oxygen (CDO) therapy, which has shown potential in healing chronic wounds such as diabetic foot ulcers.
The joint venture, which will see Belluscura act as the original equipment manufacturer (OEM), is backed by the major medical device company’s commitment to fund product development, clinical trials, and distribution following regulatory approval. The first clinical study is expected to begin outside the United States in early Q2 2025.
Belluscura’s entry into the wound care sector is timely, as the market was valued at $22.5 billion in 2023 and is forecasted to expand at a compound annual growth rate (CAGR) of 5.9% through 2032. The company’s expertise in oxygen technology positions it to capitalize on this significant market opportunity.
Bob Rauker, Chief Executive of Belluscura, highlighted the venture’s potential to leverage their technology across broader healthcare applications, addressing the substantial and growing need in the wound care market. The partnership with a globally recognized medical device company will combine Belluscura’s technological prowess with the partner’s resources and distribution capabilities.
This strategic move is poised to enhance Belluscura’s portfolio and presence in the medical device industry, as the company seeks to expand the application of its oxygen enrichment technologies to new therapeutic areas. The information for this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
